Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANTABILE: Canagliflozin vs Teneligliptin in Type 2 Diabetes With Metabolic Risks
jRCTs051180112Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in type 2 diabetes mellitus (T2DM), obesity, hypertension (HTN) and 1 more comparing Teneligliptin group with Canagliflozin group (2 arms). Primary endpoint: Composite metabolic risk endpoint. Started Feb 2018; status: completed.
02
Drugs
canagliflozinteneligliptin
03
Conditions
type 2 diabetes mellitus (T2DM)obesityhypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on jRCTs051180112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180112.